Cipla Medpro South Africa Ltd.

What Cipla Medpro South Africa Ltd. does

Cipla Medpro South Africa Ltd. is a Cape Town-based pharmaceutical manufacturer and wholly-owned subsidiary of Cipla Ltd. (India), operating as part of the broader Cipla Africa network. The company's core business is the production and supply of generic medicines — anchored by a 12-plus year track record as a supplier of antiretroviral (ARV) medicines, including TLD formulations, to the South African government through competitive tenders. It has historically participated in the government's R15.5 billion three-year ARV tender (TLD component R12.6 billion) and is currently contesting its exclusion from this contract in court alongside Hetero SA.

The company's product portfolio spans more than 20 therapeutic areas, including HIV/AIDS, tuberculosis, asthma, cardiology, oncology, diabetes, dermatology, central nervous system conditions, antibiotics, antifungals, COVID-19, pain management, women's and men's health, vitamins and supplements, and wound care. Beyond finished dosage forms, Cipla Medpro supplies Active Pharmaceutical Ingredients (APIs) and biosimilars. Manufacturing is anchored in South Africa, with recent capital investment in a Countec bottle packaging line and a 190% increase in tablet filling capacity, supporting annual production of approximately 475 million tablets. The business is regulated by SAHPRA, with all products listed in the SAHPRA Online Directory.

Cipla Medpro generates revenue primarily through two channels: (1) direct supply of ARV medicines to the South African government via competitive tenders, and (2) distribution of its broader pharmaceutical portfolio through hospitals, clinics, and pharmacies across South Africa. The company supports healthcare professional engagement through the Cipla DNA Academy portal and runs multiple public health campaigns. As a subsidiary of the publicly listed Cipla Ltd., it benefits from integration into a multinational pharmaceutical group with operations across Africa (Kenya, Ghana, Morocco, Egypt), India, the UK, the US, Brazil, Australia, Germany, Malaysia, Nepal, and Spain. The South African entity itself is privately held, with leadership including Paul Miller (Founder & CEO) and Mark Daly (CFO).

Name

Cipla Medpro South Africa Ltd.

Legal name

Cipla South Africa

Website

https://cipla.co.za

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

251–500 employees

Short description

Cipla Medpro South Africa is a Cape Town-based generic pharmaceutical manufacturer and subsidiary of India's Cipla Ltd., supplying antiretroviral medicines and a broad multi-therapy portfolio to the South African government and healthcare providers, with 475 million tablets of annual production capacity.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Immunization & Vaccine Delivery Programs (BPADAIAB), Global Supply Chain, Procurement & Market-Shaping Partnerships (Medicines/Diagnostics/Vaccines) (HLAJAOAK)

Keywords

• Generic pharmaceuticals
• Antiretroviral medicines
• Pharmaceutical manufacturing
• Government tender supply
• Multi-therapeutic portfolio

Headquarters

HQ city

Cape Town

HQ country

South Africa

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Government Tender Supply - ARV Medicines: Cipla Medpro South Africa generates revenue primarily through supplying antiretroviral (ARV) medicines to the South African government via competitive tenders. The ARV tender is valued at R15.5 billion over three years, with the TLD component accounting for R12.6 billion of that total. The company competes with other pharmaceutical suppliers for government contracts and has been a tender supplier for over 12 years.
2. Pharmaceutical Product Sales: The company manufactures and sells a broad portfolio of pharmaceutical products across multiple therapeutic areas including HIV, asthma, antibiotics, cardiology, dermatology, diabetes, oncology, pain management, and more. Products are distributed through healthcare providers and pharmacies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Cipla Medpro South Africa manufactures and supplies a broad portfolio of pharmaceutical products spanning antiretroviral (ARV) therapies, antibiotics, cardiology, oncology, diabetes, dermatology, neurology, ophthalmology, respiratory, and women's health. The company supplies medicines primarily through South African government health tenders, public healthcare institutions, and healthcare provider channels, leveraging its position within the Cipla Africa network.

Product overview

Cipla Medpro South Africa Ltd. is a pharmaceutical company operating as part of the Cipla Africa group, with over 12 years of experience supplying antiretroviral (ARV) medicines to the South African government. The company's product portfolio spans a comprehensive range of therapeutic areas including HIV/AIDS, tuberculosis, asthma, cardiology, oncology, diabetes, dermatology, and infectious diseases. Cipla offers over 20 therapy categories covering allergy, antibiotics, antifungals, central nervous system, COVID-19, deworming, gastro, hair loss, immunosuppressants, men's health, osteoporosis, pain, sexual health, women's health, wound care, and vitamins/supplements. The company manufactures both branded generic pharmaceuticals and biosimilars, with significant local production capacity including a Countec bottle line and tablet filing capability of 475 million tablets annually. The product offering is complemented by Active Pharmaceutical Ingredients supply and the Cipla DNA Academy healthcare professional portal. Cipla South Africa operates manufacturing facilities in South Africa and participates in major government tenders including the R15.5 billion Aids drug tender.

Differentiator

Problem solved

Functional benefit

Products and services

• Antiretroviral (ARV) Medicines Range of antiretroviral pharmaceutical products supplied for HIV/AIDS treatment, primarily through South African government public health tenders and healthcare provider channels.
• Antibiotic Pharmaceuticals Antibiotic medicines manufactured and distributed by Cipla Medpro South Africa for infectious disease treatment across public and private healthcare channels.
• Cardiology Pharmaceuticals Cardiovascular medicines manufactured and supplied by Cipla Medpro South Africa for the treatment of heart and circulatory conditions.
• Oncology Pharmaceuticals Oncology medicines manufactured and distributed by Cipla Medpro South Africa for cancer treatment in public and private healthcare settings.
• Diabetes Pharmaceuticals Anti-diabetic medicines produced and supplied by Cipla Medpro South Africa for the management of diabetes and related metabolic conditions.
• Dermatology Pharmaceuticals Dermatological preparations manufactured and distributed by Cipla Medpro South Africa for the treatment of skin conditions.
• Neurology Pharmaceuticals Neurological medicines supplied by Cipla Medpro South Africa for central nervous system conditions.
• Ophthalmology Pharmaceuticals Ophthalmic preparations manufactured and distributed by Cipla Medpro South Africa for the treatment of eye conditions.
• Respiratory Pharmaceuticals Respiratory medicines manufactured and supplied by Cipla Medpro South Africa for the treatment of asthma, COPD, and other respiratory conditions.
• Women's Health Pharmaceuticals Pharmaceutical products for women's health indications manufactured and distributed by Cipla Medpro South Africa.

Quantifiable outcome

• 190% increase in tablet filing capacity
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered minor.

• Hetero SAminorOthersCipla Medpro South Africa is acting alongside Hetero SA in a joint legal challenge against the South African health department regarding the R15.5bn Aids drug tender. Both companies were excluded from the tender and are contesting the exclusion in court.
• Avacare Health Group (Affected Competitors)minorOthersBarrs Pharmaceuticals Industries and Innovata Pharmaceuticals, both subsidiaries of Avacare Health, entered business rescue. This affected the ARV supply chain and created opportunity for Cipla Medpro to reaffirm its commitment to uninterrupted supply as a remaining tender supplier.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aspen Pharmacare Holdings: Largest South African pharmaceutical manufacturer and a direct competitor in ARVs, generics and government tender supply. Both companies compete head-to-head for South African Department of Health tenders and supply similar therapeutic portfolios through hospitals, clinics and pharmacies.
• Adcock Ingram Holdings: Major South African pharmaceutical manufacturer with overlapping portfolio across prescription, OTC and generic medicines. Competes with Cipla Medpro in healthcare provider distribution channels and in selected government supply contracts.
• Hetero SA: South African subsidiary of India's Hetero Labs and a direct ARV tender competitor. Hetero SA is co-litigating with Cipla Medpro on the R15.5bn Aids drug tender exclusion, making it both a legal ally and a head-to-head rival in ARV supply.

Broad incumbents

• Cipla Ltd. (Parent): Indian multinational parent company that manufactures and distributes the same ARV and generic molecules globally. Provides product supply, R&D and capital support to Cipla Medpro and is comparable in product portfolio and therapeutic breadth, though operating at vastly larger scale.
• Mylan/Viatris: Global generics and ARV powerhouse with established presence in African public health tenders. Comparable in that it supplies HIV/AIDS medicines and a broad generic portfolio to African governments and global health procurement agencies.
• Aurobindo Pharma: Indian generics manufacturer with significant ARV and emerging market exposure. Comparable through its Africa-focused generic pharmaceutical supply, including ARVs, antibiotics and TB medications delivered via tenders and distribution partnerships.
• Dr. Reddy's Laboratories: Indian multinational with a generics portfolio covering HIV, oncology, cardiovascular and other therapeutic areas overlapping with Cipla Medpro. Comparable through its emerging markets strategy and supply of affordable generic medicines to African public health channels.
• Sanofi South Africa: Multinational pharma with established South African operations across vaccines, specialty care and generics. Comparable in therapeutic breadth and government engagement, though Sanofi's portfolio skews more toward branded specialty and vaccines than Cipla's ARV-led generics base.

Emerging players

• Lupin Pharmaceuticals: Indian pharmaceutical company expanding generic and specialty portfolios into Africa. Comparable in its generic manufacturing scale and emerging-market public health focus, though with a smaller African commercial footprint than Cipla Medpro.

Others

• Roche South Africa: Multinational pharmaceutical company with South African presence in oncology, diagnostics and specialty medicines. Not a direct ARV/generic competitor but operates in the same hospital tender environment and could be a partner or competitor for higher-margin specialty products Cipla Medpro is expanding into.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ciplarsa
• YouTubeyoutube.com/user/ciplamedsa
• Facebookfacebook.com/ciplasa
• LinkedInlinkedin.com/company/cipla-southafrica
• Instagraminstagram.com/ciplaafrica

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cipla Medpro South Africa Ltd.